Your browser doesn't support javascript.
loading
Weight Gain After Simultaneous Kidney and Pancreas Transplantation.
Knight, Richard J; Islam, Ana K; Pham, Christine; Graviss, Edward A; Nguyen, Duc T; Moore, Linda W; Kagan, Anna; Sadhu, Archana R; Podder, Hemangshu; Gaber, A Osama.
Afiliación
  • Knight RJ; Department of Surgery, Houston Methodist Hospital, Houston, TX.
  • Islam AK; Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX.
  • Pham C; Department of Pharmacy, Houston Methodist Hospital, Houston, TX.
  • Graviss EA; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX.
  • Nguyen DT; Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX.
  • Moore LW; Department of Surgery, Houston Methodist Hospital, Houston, TX.
  • Kagan A; Houston Kidney Consultants, Houston, TX.
  • Sadhu AR; Department of Internal Medicine, Houston Methodist Hospital, Houston, TX.
  • Podder H; Department of Surgery, Houston Methodist Hospital, Houston, TX.
  • Gaber AO; Department of Surgery, Houston Methodist Hospital, Houston, TX.
Transplantation ; 104(3): 632-639, 2020 03.
Article en En | MEDLINE | ID: mdl-31335775
BACKGROUND: Excessive weight (EW) gain is common after solid organ transplantation, but there is little information concerning obesity after pancreas transplantation. The study goal was to characterize EW gain after kidney-pancreas (KP) transplantation. METHODS: This was a retrospective single-center review of 100 KP recipients transplanted between September 2007 and June 2015. RESULTS: The median percent weight gain for all recipients at 1 year posttransplant was 10% (interquartile range, 2.7%-19.3%) of baseline weight. EW gain, defined as greater than or equal to a 19% 1-year increase in weight, included all recipients (n = 26) above the upper limit of interquartile range for weight gain at 1 year. In multivariate analysis, recipient age <40 years, the use of tacrolimus/mammalian target of rapamycin immunosuppression, and an acute rejection event were independent risk factors for EW gain. At a mean follow-up of 43±23 months, there was no difference in patient or graft survival between the EW and non-EW cohorts. Although mean hemoglobin A1c levels between groups were equivalent, the EW versus non-EW cohort displayed a significant increase in mean insulin levels and a trend towards higher C-peptide levels. Criteria for posttransplant metabolic syndrome was met in 34.6% of EW versus 17.6% of non-EW cohorts (P = 0.07). CONCLUSIONS: At intermediate-term follow-up, EW gain after KP transplantation was not associated with an increased risk of death or graft loss, although there was a trend toward a greater risk of posttransplant metabolic syndrome. There may be a metabolic consequence of successful pancreas transplantation that results in EW gain in a proportion of recipients, leading to an increased risk of long-term cardiovascular complications.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aumento de Peso / Trasplante de Riñón / Trasplante de Páncreas / Síndrome Metabólico / Diabetes Mellitus Tipo 2 / Obesidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplantation Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Aumento de Peso / Trasplante de Riñón / Trasplante de Páncreas / Síndrome Metabólico / Diabetes Mellitus Tipo 2 / Obesidad Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Transplantation Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos